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Background: Previous study demonstrated that miR-133a was released into blood from injured myocardium in
cardiovascular diseases. However, the dynamic change of circulating miR-133a level in the early phase of acute
myocardial infarction (AMI) and the correlation between miR-133a and severity of coronary stenosis in coronary
heart disease (CHD) patients are not clear.
Methods and results: Three different cohorts (including 13 AMI patients, 176 angina pectoris patients and
127 control subjects) were enrolled to investigate the expression levels of circulating miR-133a in patients with
myocardial ischemia and also the relationship between plasma miR-133a and severity of coronary stenosis.
Plasma miR-133a levels of participants were examined by real-time quantitative PCR. Simultaneously, plasma
cardiac troponin I (cTnI) concentrations were measured by ELISA assays. The results showed that circulating
miR-133a level was significantly increased in AMI patients in time-dependent manner, and achieved a 72.1 fold
peak at 21.6 ± 4.5 hours after the onset of AMI symptoms and exhibited a similar trend to plasma cTnI level. We
also found that plasma miR-133a levels were higher in CHD patients than control group. Importantly, the levels
of circulating miR-133a positively correlated with the severities of the coronary artery stenosis. Receiver operating
characteristic (ROC) analysis revealed that circulating miR-133a had considerable diagnostic accuracy for CHD
with an AUC of 0.918 (95% confidence interval 0.877-0.960).
Conclusions: Circulating miR-133a may be a new biomarker for AMI and as a potential diagnostic tool. And
increased miR-133a level may be used to predict both the presence and severity of coronary lesions in
CHD patients.
Keywords: Biomarker, CHD, Circulating miRNAIntroduction
Acute myocardial infarction (AMI) is the worst acute
syndrome of coronary heart diseases (CHD) with high
morbidity and mortality. An early and correct diagnosis
is critical for providing appropriate therapy to improve
the survival rate and prognosis [1]. Blood biomarker* Correspondence: chenchen@tjh.tjmu.edu.cn
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reproduction in any medium, provided the orcardiac troponin I (cTnI) is widely used in clinical practice
as the gold standard for diagnosing acute myocardial
infarction [2], but plasma cTnI concentrations may be
falsely elevated in certain cardiac as well as non cardiac
diseases such as severe heart failure, atrial fibrillation,
chronic kidney disease, severe sepsis and septic shock
[3-6]. Therefore, it is necessary to search novel biomarkers
with high sensitivity and specificity for early diagnosis
of AMI.
MicroRNAs (miRNAs) are endogenous small non-coding
RNAs with 21-25 nucleotides in length. By pairing with
the 3’ UTR of target mRNAs, miRNAs can regulate
protein-coding genes at the posttranscriptional level viatd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[7]. At present, About 700 human miRNAs have been
identified, and most of them were found to be tissue-/
cell-specific [8]. Mounting evidences suggest that miRNAs
play crucial roles in various physiological and pathologic
processes, and the dysfunctions of miRNAs are associated
with various diseases and pathophysiologies [9-11]. Re-
cently, studies showed that miRNAs are abundantly
present in body fluid and can be used as biomarkers for
some diseases [12-14]. MiR-133a is a muscle specific-
miRNA and is expressed abundantly in myocardial cells
[15-17]. It has been established that miR-133a plays
important roles in myogenesis, cardiac development and
hypertrophy [18-23]. Previous studies demonstrated that
miR-133a had a low level presence in the plasma of
healthy people [15], and it was expressed differentially
in different cardiovascular diseases [15,24]. Recently, it
has been reported that the elevated miR-133a is released
into peripheral circulation from the injured myocardium
after Ca2+ stimulation [25]. Although these studies demon-
strated that the expression of circulating miR-133a in-
creased in patients with CHD (including AMI and angina
pectoris) and circulating miR-133a can be used as a
marker for cardiomyocyte death, few clinical studies
have reported on the dynamic change in circulating miR-
133a level in the early phase of AMI, and also the correl-
ation between miR-133a concentration and the severity
of coronary stenosis in CHD patients is not clear.
In the present work, we aimed to confirm the role of
plasma miR-133a as a biomarker for CHD, especially
for AMI. Furthermore, we investigated the correlation
between the levels of circulating miR-133a and the
Gensini score (a numerical value for assessment the




Experiments were conducted in accordance with the
Declaration of Helsinki. Three cohorts participated in this
study.
The first cohort included 13 patients of AMI and 27
healthy volunteers. The inclusion criteria for AMI patients
were based on the third Universal Definition of Myocar-
dial Infarction [26]. Briefly, AMI patients were clinically
diagnosed by the following criteria: 1) acute ischemic
chest pain within 24 hours; 2) electrocardiogram change
of acute myocardial infarction (pathological Q wave,
ST-segment elevation or depression); 3) plasma cTnI >
0.1 ng/mL. The initial blood sample (denoted by T0)
was collected immediately after the AMI patient was
admitted to Tongji hospital. Other 5 subsequent blood
samples were obtained at 4, 12, 24, 48, 72 hours after
the first collection, denoted by 4 h, 12 h, 24 h, 48 h and72 h, respectively. The second cohort included 22 CHD
patients with chest pain having single lesion of the left
anterior descending coronary artery and 8 non-CHD
patients with negative results of coronary angiography.
The third cohort contained 246 patients with acute
chest pain. Further, coronary angiography showed that
154 of them were CHD patients with complex lesions
of coronary artery, and the remaining 92 patients were
non-CHD patients with no coronary artery stenosis. A
single blood sample from each participant in both
second and third cohorts was obtained immediately
after admission, and coronary angiography was used to
confirm CHD and define the coronary artery lesions.
Blood samples were collected via venous puncture. After
isolation by centrifugation, the plasma were transferred to
RNase-free tubes and stored at -80°C until further
processing.
Participants were selected from inpatients or outpatients
departments of Tongji hospital between October 2009
and June 2011 in Wuhan, China. The study was approved
by the Medical Ethics Committee in Tongji Hospital
and written informed consents were obtained from all
the participants.
RNA isolation
Total RNAs were isolated by TRIzol LS Reagent (Invi-
trogen) according to the manufacturer’s protocol as de-
scribed previously [27]. In brief, total RNA was purified
from 500 μL of plasma and ultimately eluted into 25 μL
of RNase-free water.
Detection and quantification of miRNAs by real-time PCR
Two microgram of total RNA was reverse-transcribed
using Transcript First-strand cDNA synthesis SuperMix
(TransGen Biotech, Beijing, China) according to the
manufacturer’s protocol. The Bulge-Loop™ miRNA qRT-
PCR Detection Kit (Ribobio Co., Guangzhou, China) and
SYBR Green PCR SuperMix Kit (TransGen Biotech,
Beijing, China) were used in real-time PCR for examining
the relative quantification of miR-133a according to the
manufacturer’s protocol with the Rotor-Gene 6000 system
(Corbett Life Science, QIAGEN, Hilden, Germany), and
U6 was measured as endogenous control for normalizing
the data of experimental qRT-PCR. Each specimen was
measured in triplicate. The threshold cycle (Ct) was de-
fined as the fractional cycle number at which fluorescence
exceed the threshold. In our experiment the detection
limit of Ct value was defined as 40. The Ct values from
qRT-PCR assays over 40 were treated as 40 [15,25,28,29].
Cardiac troponin I determination
The concentrations of cardiac Troponin I (cTnI) were
measured by the Human Troponin I ELISA kit (Abnova,
Taiwan) according to manufacturer’s protocol.
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Real-time PCR assays were analyzed by 2-ΔΔct method,
which is a widely used method to present relative gene
expression by comparative Ct. All the data of patients’
clinical characteristics are described as mean ± SD, and
the other data are described as mean ± SEM. The data
of miR-133a and cTnI were analyzed by the Kolmogorov-
Smirnov test to examine whether they followed the nor-
mal distribution. If the data fit the normal distribution,
then student’s t test and the ANOVA are used. Otherwise,
Mann–Whitney U test and two-tailed Kruskal-Wallis tests
are performed. In this study, both the data of miR-133a
and cTnI were found to follow the normal distribution
by the Kolmogorov-Smirnov test and hence student’s t
test and ANOVA were used. Categorical variables were
compared by χ2 test. The correlation analyses were
determined by linear regression analysis. The receiver
operating characteristic (ROC) curve was used to assess
the predictive power for diagnosing CHD. Multiple logistic
regression analysis was carried out to investigate whether
miRNA-133a was an independent predictor of CHD after
adjustment for relevant co-variants (including age, sex,
smoking and cardiovascular risk factors hypertension,
diabetes, hyperlipidemia etc.) as previously described
[30]. All statistical analyses were accomplished by usingFigure 1 Expression pattern of circulating miR-133a and cTnI in AMI p
in AMI patients at various time points; (C) Time courses of circulating miR-1
and cTnI in plasma from AMI patients. Data were presented as mean ± SEM
versus peak expression (Statistical methods: ANOVA and linear regression aSPSS 17.0 software, and the cutoff point of statistical
significance was set at p < 0.05 (two-sided).
Results
The real-time RT-PCR (qRT-PCR) assay for
miRNA quantification
To ensure the method of qRT-PCR assay for miR-133a
quantification is viable and suitable, the amplification curves
for both miR-133a and U6 were provided (Additional file 1:
Figure S1A and B). To verify primer specificities, melting
curve analyses (Additional file 1: Figure S1C and D) and
agarose gel electrophoresis images (Additional file 1: Figure
S2A and B) were performed, the RNAs extracted from
mouse heart and brain were treated as positive and
negative control, respectively.
The pattern of plasma miR-133a levels in acute
myocardial infarction
Firstly, 13 AMI patients and 27 healthy volunteers were
selected in the first cohort to test whether circulating
miR-133a could serve as a novel biomarker of AMI. The
baseline clinical characteristics of the first cohort are
shown in Additional file 1: Table S1. There were no
significant differences in age, sex, blood pressure, fasting
glucose and other biochemical parameters between AMIatients. (A and B) The expressions of circulating miR-133a and cTnI
33a and cTnI in AMI patients; (D) The correlation between miR-133a
, *p < 0.05, **p < 0.01 versus healthy control; #p < 0.05, ##p < 0.01
nalysis were used as appropriate).
Figure 2 Expression pattern of circulating miR-133a and cTnI in CHD patients with single stenosis in the proximal of left anterior
descending coronary artery. (A and B) The expressions of circulating miR-133a and cTnI in CHD patients with single stenosis of coronary artery;
(C) The correlation between plasma miR-133a and the degree of coronary atherosclerotic stenosis in CHD patients with single stenosis in the
proximal of left anterior descending coronary artery. Data were presented as mean ± SEM, *p < 0.05, **p < 0.01, NS, not significant versus non-
CHD chest pain patient (Statistical methods: Student’s t test and linear regression analysis were used as appropriate).
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obtained from each AMI patient at various time points
(T0h, 4 h, 12 h, 24 h, 48 h, and 72 h) to investigate the
dynamic change trend in circulating miR-133a level in
the early phase of AMI. The first plasma sample was
collected at 17.6 ± 4.5 hours after the onset of AMI
symptoms (T0h), and other 5 collecting time points were
4 h, 12 h, 24 h, 48 h, and 72 h after T0. As shown in
Figure 1A, circulating miR-133a concentrations were
significantly increased in the early phase (the first 3
time points) after the occurrence of AMI in all patients
compared with controls. To get a more intuitive look at
the data, we also presented data using scatter plots
(Additional file 1: Figure S3A). In those patients, circulating
miR-133a achieved a peak (~72.1 fold) at 4 h, and showed
a tendency to gradually return close to its control level
over the next 3 days. The concentrations of cTnI were
measured in the same blood samples from AMI patients,
simultaneously. Interestingly, cTnI remarkably increased
in the early phase of AMI and achieved a peak (~2445.2
fold) at 4 h resembling miR-133a (Figure 1B). They both
exhibited the same trend in the early phase of AMI
with the elevated peak at 4 h, and then graduallydeclined close to their normal level over the next 3 days
(Figure 1C). Furthermore, correlation analysis showed a
positive correlation between circulating levels of miR-133a
and cTnI concentrations in AMI patients (Figure 1D). These
data suggested that circulating miR-133a may be regarded
as a novel biomarker of acute myocardial infarction.
The correlation between plasma miR-133a levels and the
severities of coronary lesion in CHD patients
To investigate whether circulating miR-133a expression
correlates with the severity of coronary artery stenosis
in CHD patients, 22 CHD patients with single stenotic
lesion in the proximal left anterior descending coronary
artery and 8 non-CHD patients with negative results of
coronary angiography were recruited in the second cohort.
Based on the severity of coronary artery stenosis, the
participants were divided into 4 groups (Additional file
1: Table S2). The first group consisted of 8 CHD patients
with severe coronary artery stenosis (81%~ 100%, LAD 1);
the second group contained 7 CHD patients with moder-
ate coronary artery stenosis (51%~ 80%, LAD 2); the third
group consisted of 7 CHD patients with mild coronary
artery stenosis (30% ~ 50%, LAD 3); the fourth group
Figure 3 Expression pattern of circulating miR-133a and cTnI in validation cohort of CHD patients. (A and B) The expressions of
circulating miR-133a and cTnI in CHD patients with complex stenosis of coronary artery; (C and D) The correlation between circulating miR-133a,
cTnI and the Gensini scores in total CHD patients. Data were presented as mean ± SEM, *p < 0.05, **p < 0.01 versus non-CHD chest pain patient
(Statistical methods: Student’s t test and linear regression analysis were used as appropriate).
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coronary angiography (non-CHD). Their characteristics
are summarized in Additional file 1: Table S3. MiR-133a
quantitative analysis showed that circulating miR-133a
levels were significantly elevated in both LAD 1 and LAD
2 groups, especially in LAD 1 (~5-fold), compared to non-
CHD patients, and the levels of miR-133a in LAD 3
showed no significant difference compared with non-
CHD patients (Figure 2A and Additional file 1: Figure
S3B). The concentration of plasma cTnI was not sig-
nificantly different among the subgroups, although it
was slightly higher in the first and second groups
(Figure 2B). Linear regression analysis showed that the
levels of plasma miR-133a positively correlated with
the severity of coronary artery stenosis in CHD patients
with single left anterior descending coronary athero-
sclerosis (Figure 2C), but there was no association be-
tween plasma cTnI and the degree of coronary stenosis.
These results indicated that elevated miR-133a in
plasma was better than cTnI for reflecting the severity
of coronary artery stenosis in non-AMI CHD patients
with single stenotic lesion of left anterior descending
coronary artery.The correlation between circulating miR-133a levels and
the gensini score in a validation cohort with a large
number of CHD patients
The results obtained in the second cohort were then val-
idated in a third cohort of 246 patients with acute chest
pain. Among them, 154 patients had angiographically
documented CHD, and the remaining 92 patients without
evidence of CHD were selected as control (non-CHD
patients). The baseline characteristics of this cohort are
presented in Additional file 1: Table S4. All of these 154
CHD patients were assessed by Gensini score in order
to evaluate the severity of coronary lesions. Our results
showed a 4.5 fold increase of circulating miR-133a levels
and an 87 fold increase of plasma cTnI concentrations
in CHD patients compared with non-CHD chest pain pa-
tients, respectively (Figure 3A and B), and scatter plots on
miR-133a levels more clearly illustrated these differences
and distribution (Additional file 1: Figure S3C). Using the
linear regression model, the relationship between circulat-
ing miR-133a (or cTnI) and Gensini score in 154 CHD
patients were analyzed. The results showed that the levels
of circulating miR-133a moderately correlated with Gensini
scores in CHD patients (Figure 3C), while plasma cTnI did
Figure 4 Expression pattern of circulating miR-133a and cTnI in subgroups of CHD patients. (A and B) The expressions of cTnI and
circulating miR-133a in subgroups of CHD patients with complex stenosis of coronary artery; (C and D) The correlation between circulating miR-
133a and the Gensini scores in patients from group 1 and group 2; Data were presented as mean ± SEM, *p < 0.05, **p < 0.01 versus non-CHD
chest pain patient (Statistical methods: Student’s t test and linear regression analysis were used as appropriate).
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Further, the plasma cTnI concentrations from 140 of 154
CHD patients were detected simultaneously. 72 of these
140 CHD patients had high levels of plasma cTnI, approxi-
mately 169-fold increase as compared with non-CHD pa-
tients (Figure 4A); but the remaining 68 CHD patients had
very low levels of cTnI (≤ 0.05 ng/mL), which were not
consistent with the severity of coronary artery stenosis.
Further, in order to determine whether the expression of
circulating miR-133a in CHD patients is superior to cTnI
in the detection of the severity of coronary artery stenosis,
140 CHD patients were divided into 2 subgroups on the
basis of cTnI levels (Figure 4A). The plasma miR-133a level
increased ~5.5-fold and ~3.8-fold in group 1 and group 2,
respectively, compared with non-CHD patients (Figure 4B).
Moreover, in subgroup analysis, we found that plasma
miR-133a level significantly correlated with Gensini score
of coronary artery lesions in both subgroups of CHD
patients (Figure 4C and D). However, the concentration
of cTnI showed no correlation with the Gensini score
in the two subgroups. These observations demonstrated
that plasma miR-133a significantly correlated with the
Gensini score of coronary lesions in CHD patients.
The plasma miR-133a is a sensitive predictor for coronary
heart disease
To investigate the role of circulating miR-133a as a sen-
sitive predictor for CHD, ROC analysis was performedin the third cohort (Additional file 1: Table S5). The clin-
ical model with age, sex, smoke and other cardiovascular
risk factors (hypertension, diabetes, hyperlipidemia etc.)
resulted in an AUC of 0.785 (95% confidence interval
0.713-0.857) for the third cohort to differentiate between
CHD and non-CHD groups (Figure 5A). The ROC curve
of cTnI showed a moderate separation, with an area under
the ROC curve (AUC) of 0.741 (95% confidence interval
0.668-0.814). Interestingly, ROC curve of circulating miR-
133a showed a much higher AUC of 0.918 (95% confi-
dence interval 0.877-0.960). It is noteworthy that addition
of miR-133a to the clinical model and cTnI remarkably
increased the diagnostic value for CHD with an AUC of
0.942 (95% confidence interval 0.908-0.976) and 0.925
(95% confidence interval 0.887-0.963), respectively. Adding
miR-133a to the clinical model with cTnI (AUC of 0.834,
95% confidence interval 0.773-0.896) significantly increased
the AUC to an even higher value of 0.947 (95% confidence
interval 0.915-0.979). Furthermore, the ROC curves of
circulating miR-133a in both the subgroups of CHD
were determined (Additional file 1: Table S6). MiR-133a
also had significant differentiation value for CHD and
non-CHD in both group 1 and group 2 with the AUC of
0.981 (95% confidence interval 0.962-1.0) and 0.885 (95%
confidence interval 0.827-0.942), respectively (Figure 5B
and C). The diagnostic value for CHD was significantly
increased with the addition of miR-133a to cTnI in the
two subgroups with the AUC of 0.953 (95% confidence
A all CHD patients B CHD patients (cTnI >0.05ng/ml) 
C CHD patients (cTnI ≤0.05ng/ml) 
Figure 5 Diagnostic value of cardiac troponin I and circulating miR-133a in CHD patients. (A) Total CHD patients compared to non-CHD
patients in the third cohort; (B) CHD patients from group 1 compared to non-CHD patients in the third cohort; (C) CHD patients from group 2
compared to non-CHD patients in the third cohort (Statistical methods: receiver operating characteristic (ROC) curve and multiple logistic
regression analysis).
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0.836-0.947), respectively. Taken together, these data sug-
gested that circulating miR-133a may be a sensitive and
independent predictor for CHD.Discussion
Previous studies demonstrated that miRNAs are abun-
dantly present in a remarkably stable form and they can
be detected in peripheral circulation [12,31]. Recently,
more and more circulating miRNAs, including heart-,
vascular- and muscle-specific miRNAs, have been reported
as new biomarkers in multiple cardiovascular diseases
[32,33]. For example, circulating miR-423-5p is suggested
as a biomarker for heart failure [34]. And additionally,
cardiac-related miRNAs (miR-208, miR-499 and miR-1)
and stress-related miRNAs (miR-21 and miR-146a) may
be potential biomarkers for acute coronary syndrome [30].
Moreover, a recent study had reported that circulating
miR-126, miR-223 and miR-197 were consistently and
significantly related to incidence of myocardial infarction
[35]. These observations suggest that circulating miRNAs
may be useful not only for prediction of cardiovascularevents, but also serve as sensitive biomarkers for improv-
ing the diagnostic accuracy of cardiovascular diseases.
The present study demonstrated dynamic change in
circulating miR-133a expression in the early phase of
acute myocardial infarction. Furthermore, our data is the
first to demonstrate a positive correlation between cir-
culating miR-133a and the severity of coronary stenosis
in CHD patients.
The results demonstrated that circulating miR-133a
levels increased in time-dependent manner in the early
phase of AMI and exhibited a similar trend as cTnI in
AMI patients; both of them rapidly increased at first,
achieved a peak at 21.6 ± 4.5 hours after the onset of
AMI symptoms, and then gradually returned close to
normal level on the following days. Importantly, the
circulating miR-133a positively correlated with cTnI in
AMI patients. These results strongly indicated that
circulating miR-133a can be a biomarker for diagnosing
acute myocardial infarction.
Furthermore, 22 CHD patients with single lesion of
coronary artery were included in the second cohort to
study the relationship between plasma miR-133a and the
severity of coronary atherosclerosis. The results showed
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pared with non-CHD patients, and the levels of elevated
miR-133a positively correlated with the severities of
coronary atherosclerosis. The results were further verified
in a large validation cohort of 246 subjects (154 CHD
patients and 92 non-CHD). Interestingly, we found a
higher expression of circulating miR-133a in CHD patients
with low cTnI expression compared with non-CHD
patients and it correlated with Gensini score of these
CHD patients. These results showed that circulating
miR-133a is superior to cTnI in detecting the severity
of coronary artery lesions.
Finally, the ROC curve of miR-133a and cTnI were
plotted in CHD patients with an AUC of 0.918 and
0.741, respectively. The ROC curves of CHD subcategories
revealed that circulating miR-133a is more informative for
CHD diagnosis than cTnI in CHD patients. Importantly,
the diagnostic accuracy for CHD became significantly
raised when combining clinical model, miR-133a and
cTnI with the AUC of 0.947. Interestingly, this addition
effect of combination could be more valuable for cTnI to
improve the diagnostic accuracy of CHD, while miR-133a
appeared to be a strong and independent predictor for
CHD. These results may provide theoretical foundation
in improving the clinical diagnosis of CHD.
In summary, the present study measured the early
changes in expressions of circulating miR-133a in AMI
patients, and provided first insights into the relationship
between plasma miR-133a and the severity of coronary
atherosclerotic stenosis in CHD patients, our results sug-
gested that circulating miR-133a was a sensitive predictor
for diagnosing AMI and CHD.
All these results suggested that circulating miR-133a
can be a novel and potent biomarker for CHD, especially
for AMI. And its level in plasma can reflect the severity
of coronary atherosclerosis in CHD patients.
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